Free tool
Drug Trial Radar: Endocrinology and women's health
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
7
Active, not recruiting, industry sponsors, Endocrinology and women's health, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed188
7 trials
Showing 1 to 7, recently updated first.
- Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeActive, not recruiting
Corcept TherapeuticsIndustry
NCT03604198 · 125 participants · Start May 7, 2018 · Primary completion Dec 2026
Drug: relacorilant · For: Cushing Syndrome
Sites: Phoenix, Arizona; Stanford, California; Torrance, California · 48 sites in all
- Study Evaluating ABCL635 for Vasomotor Symptoms of MenopausePivotal-lookingActive, not recruiting
AbCellera Biologics Inc.Industry
NCT07118891 · 136 participants (planned) · Start Jun 23, 2025 · Primary completion Feb 2027
Drug: ABCL635; Placebo · For: Vasomotor Symptoms Associated With Menopause; Healthy Volunteers
Sites: Calgary, Canada; Red Deer, Canada; Vancouver, Canada · 13 sites in all
- A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With EndometriosisPivotal-lookingActive, not recruiting
Gesynta Pharma ABIndustry
NCT07260669 · 213 participants · Start Oct 15, 2025 · Primary completion Jun 2027
Drug: Vipoglanstat; Placebo · For: Endometriosis
Sites: Blagoevgrad, Bulgaria; Sofia, Bulgaria; Brno, Czechia · 44 sites in all
- A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult ParticipantsPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT06345339 · 2,701 participants · Start Apr 26, 2024 · Primary completion Sep 2027
Drug: Armour Thyroid; Levothyroxine · For: Hypothyroidism
Sites: Birmingham, Alabama; Bonita, California; Burbank, California · 139 sites in all
- A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04214288 · 240 participants · Start Apr 22, 2020 · Primary completion Aug 30, 2022
Drug: AZD9833; Fulvestrant · For: Advanced ER-Positive HER2-Negative Breast Cancer
Sites: Birmingham, Alabama; Long Beach, California; Fort Myers, Florida · 85 sites in all
- A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)Pivotal-lookingActive, not recruiting
Angitia BiopharmaceuticalsIndustry
NCT06577935 · 379 participants · Start Oct 31, 2024 · Primary completion Dec 2026
Drug: AGA2118 · For: Postmenopausal Osteoporosis
Sites: Birmingham, Alabama; Gainesville, Georgia; Albuquerque, New Mexico · 23 sites in all
- PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212)Active, not recruiting
Lumos PharmaIndustry
NCT04806854 · 24 participants (planned) · Start Jul 14, 2021 · Primary completion Apr 2030
Drug: LUM-201 · For: Growth Hormone Deficiency
Sites: Santiago, Chile
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.